Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL645910 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL19253810 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL11153523 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL19253788 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL6573992 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL3688686 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL6572425 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL25283986 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL727987 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 | |
| SCHEMBL6574079 | 0.98 | DNM1 (0.49) | MEN1KMT2AMAPK1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117769588-B | Methods and reagents for enhancing chemiluminescent signals | 欧蒙医学实验诊断股份公司 | 2025-02-21 | — | — | CN | claimed |
| US-20240353412-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2024-10-24 | — | — | US | claimed |
| CN-117769588-A | Methods and reagents for enhancing chemiluminescent signals | 欧蒙医学实验诊断股份公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117696259-A | Method for simultaneously and efficiently removing impurities and whitening phosphogypsum | 中南民族大学 | 2024-03-15 | — | — | CN | claimed |
| EP-4146765-B1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-07-05 | — | — | EP | claimed |
| US-20230111238-A1 | STABLE COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | claimed |
| WO-2023043854-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | claimed |
| CN-115039774-A | Compound disinfectant for controlling banana march disease and panama disease and application thereof | 苏州艾科尔化工科技有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-111186901-B | Technology for feeding ozone into multistage ozone reaction tower by ejector | 辽宁中舟得水环保科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-111186901-A | Technology for feeding ozone into multistage ozone reaction tower by ejector | 辽宁中舟得水环保科技有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-20090143476-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| EP-0764676-B1 | Method of preparing polycarbonate-polysiloxane block copolymers | GEN ELECTRIC (US) | 2004-04-28 | — | — | EP | claimed |
| EP-4486753-B1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12565505-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12403192-B2 | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-09-02 | — | — | US | disclosed |
| CN-117769588-B | Methods and reagents for enhancing chemiluminescent signals | 欧蒙医学实验诊断股份公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-0132543-B1 | ISOMERIZATION OF ALLYLIC HALIDES WITH QUATERNARY SALTS | Union Camp Corporation (US) | 1986-10-08 | — | — | EP | disclosed |
| EP-0132544-A1 | Hydrohalogenation of conjugated dienes | Union Camp Corporation (US) | 1985-02-13 | — | — | EP | disclosed |
| EP-0132543-A1 | Isomerization of allylic halides with quaternary salts | Union Camp Corporation (US) | 1985-02-13 | — | — | EP | disclosed |
| US-3990983-A | CHLORINATED TRISODIUM PHOSPHATE, TRISODIUM CARBOXYMETHYLOXYSUCCINATE, SODIUM SULFATE, SODIUM SILICATE | LEVER BROTHERS COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565505-B2 | mTORC modulators and uses thereof | RICTOR, MTOR, RPTOR | CHRM2 4324/4885CHRM1 4410/4885CHRM3 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.